Upfront Oxaliplatin-Fluoropyrimidine Chemotherapy and Somatostatin Analogues in Advanced Well-Differentiated Gastro-Entero-Pancreatic Neuroendocrine Tumors.

Cancers (Basel) · 2025 · PMC12071586 · PMID 40361487

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a significant trendno p-value reported

A significant trend towards survival benefit emerged based on Ki67 values above or below 15%, in line with the literature.

also in 9,775 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.